Colt Ventures

Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.

EBY, LLC is a New York-based company that specializes in women's underwear and lingerie, offering a range of products designed for various shapes and sizes. Founded in 2017, EBY operates on a membership model that includes a subscription service for its intimate apparel. The company emphasizes empowerment by positioning underwear as a tool for self-confidence rather than seduction. A notable aspect of its business model is the commitment to social impact, with 10% of net sales directed to the Seven Bar Foundation. This initiative provides microfinance loans to women in need, enabling them to start or grow their businesses and break the cycle of poverty. EBY's unique patented flocking technology enhances the comfort and fit of its products, ensuring a second-skin feel for customers.

Rumble Inc. operates a video management platform that allows users to watch, share, and upload videos. Founded in 2013 and based in Toronto, Canada, Rumble provides a free-to-use service where users can engage with content by liking, commenting, and subscribing to channels. The platform also features video-on-demand and live streaming capabilities. A key element of Rumble's offering is its rights management technology, utilizing a machine learning algorithm called Rumble Rank, which enhances video verification, clearance, discovery, and licensing for user-generated content. In a short span, Rumble has established itself as a significant player in the online video space, ranking among the top 50 video destinations according to ComScore, with a substantial portion of its revenue generated from the United States.

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK pathway. Founded in 2018 and headquartered in San Diego, California, Erasca utilizes its oncology pattern recognition algorithm (OPRA), an artificial intelligence-driven drug discovery platform, to analyze large-scale data sets and uncover novel tumor biology that can inhibit key cancer pathways. The company is advancing multiple drug candidates, including Naporafenib, an innovative pan-RAF inhibitor aimed at treating NRAS mutant melanoma and other RAS/MAPK-driven tumors, as well as ERAS-007 and ERAS-601, which are oral inhibitors targeting ERK1/2 and SHP2, respectively. Through collaborations with academic and biopharmaceutical partners, Erasca aims to expand its pipeline and provide new therapeutic options for cancer patients.

ReCode Therapeutics is a biopharmaceutical company that focuses on developing precision medicines for pulmonary diseases, particularly targeting rare conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company has created a non-viral lipid nanoparticle platform that facilitates the targeted delivery of genetic therapies. This innovative technology aims to deliver corrective or disease-modifying therapies to specific organs and tissues, addressing the limitations of current gene therapy methods. By improving the precision of drug delivery, ReCode Therapeutics seeks to provide new treatment options for patients with unmet medical needs, particularly in the realm of life-limiting respiratory diseases.

ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.

Bonti, Inc. is a biotechnology company focused on developing neurotoxin products for both aesthetic and therapeutic uses. The company specializes in botulinum neurotoxin serotype E, with its primary products being EB-001A for aesthetic applications and EB-001T for therapeutic purposes. Originally founded as Endurance Biotech in 2015, the company rebranded to Bonti, Inc. in August of the same year. Based in Newport Beach, California, Bonti operates as a subsidiary of Allergan plc as of October 2018. The founding team includes Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad.

Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide. Ignyta was incorporated in 2011 and operates in San Diego, California.